Specify a stock or a cryptocurrency in the search bar to get a summary
Tourmaline Bio Inc.
TRMLTourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Address: 27 West 24th Street, New York, NY, United States, 10010
Analytics
WallStreet Target Price
58.33 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TRML
Dividend Analytics TRML
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-3581 %Dividend History TRML
Stock Valuation TRML
Financials TRML
Results | 2019 | Dynamics |